Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Stadlbauer, V; Komarova, I; Klymiuk, I; Durdevic, M; Reisinger, A; Blesl, A; Rainer, F; Horvath, A.
Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis.
Liver Int. 2020; [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Blesl Andreas
Durdevic Marija
Horvath Angela
Klymiuk Ingeborg
Komarova Irina
Rainer Florian
Reisinger Alexander Christian
Stadlbauer-Köllner Vanessa

Dimensions Citations:

Plum Analytics:
Number of Figures: 6
| | | | | |
Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment-related factors affect microbiome composition most distinctively. 16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA-effect size and least absolute shrinkage and selection operator regularized regression. Disease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C-reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses. Our cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding. NCT01607528. © 2020 The Authors. Liver International published by John Wiley & Sons Ltd.

Find related publications in this database (Keywords)
disease severity
proton pump inhibitor
© Med Uni Graz Impressum